Core Viewpoint - Nanjing Pharmaceutical has experienced significant stock price increases following the announcement of plans to acquire a domestic pharmaceutical technology asset group, although it remains uncertain if this will constitute a major asset restructuring [2][10]. Stock Performance - Nanjing Pharmaceutical's stock price surged by 20% to 14.28 CNY per share on July 30, with a total market capitalization of 3.918 billion CNY [2]. - The stock's price deviation over three trading days from July 28 to July 30 reached a cumulative increase of 30% [5]. - On July 29, the stock saw a late surge, closing with a 17.01% increase, while on July 30, it hit the daily limit up, closing with a 20% increase [6][8]. Institutional Investment - The top five buying and selling accounts on July 29 and 30 were all institutional accounts, with the largest purchases amounting to approximately 88.96 million CNY and 100 million CNY respectively [8]. Company Operations - Nanjing Pharmaceutical reported that its daily operations are normal, with no significant changes in market conditions or internal production [9]. - The company is in the process of planning the acquisition of a domestic pharmaceutical technology asset group but has not yet signed any agreements [10]. Financial Performance - Nanjing Pharmaceutical has faced declining financial performance, with net profits for 2022, 2023, and projected 2024 being -78.83 million CNY, -10.87 million CNY, and -357 million CNY respectively [10]. - The company has adjusted its sales strategies and reduced prices for some core products due to increased market competition and changes in industry policy, leading to a significant drop in revenue and gross margin [11]. Market Demand - In the first quarter of 2025, the market demand for anti-influenza virus products was lower than expected, prompting the company to lower prices for some products due to competitive pressures [15].